US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE), SORBONNE UNIVERSITE, UNIVERSITE DE PARIS on Jan. 13 for "Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis" (French Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,523,663, issued on Jan. 13, was assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE) (Paris), SORBONNE UNIVERSITE (Paris) and UNIVERSITE DE PARIS (Paris).

"Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis" was invented by Pierre-Louis Tharaux (Paris), Carole Henique-Greciet (Paris) and Martin Flamant (Paris).

According to the abstract* released by the U.S. Patent & Trademark Office: "The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade ...